

Date: 14th August, 2025

To,

Listing Compliances, BSE Limited, P. J. Towers, Fort, Mumbai - 400001. Scrip Code: 539938; Scrip Id: MIL	Listing Compliances, CSE - India, 7, Lyons Range, Dalhousie Kolkata - 700001.
--	---

Subject: Outcome of Board Meeting and Compliances of Regulation 30, 33 and 42 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30, 33 and 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., August 14, 2025, inter alia, considered and approved:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on June 30, 2025 along with Limited review report issued by M/s. V Goswami & Co, Statutory Auditors of the Company.
2. Notice of Annual General Meeting, Board's report along with Annexures thereon.
3. The Annual General Meeting of the Company will be held on Tuesday, 30th September, 2025 at 02:00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
4. The cut-off date for the purpose of the Annual General Meeting is 23rd September, 2025.
5. The Register of members and share transfer books will remain closed from 24th September, 2025 to 30th September, 2025 (both days inclusive) for the purpose of the AGM.
6. The e-voting will commence from Saturday, 27th September, 2025 at 9:00 A.M. and shall conclude on Monday, 29th September, 2025 at 5:00 P.M.
7. Mr. Yash Mehta, Practicing Company Secretary has been appointed as Scrutinizer for the purpose of e-voting at Annual General Meeting.

Further, please find enclosed "Standalone and Consolidated unaudited Financial Results along with Limited Review Report" for the quarter ended on June 30, 2025 as **Annexure 1** and same is also available on the website of the Company viz. www.medicointercontinental.com

The Board Meeting of the Company commenced at 01:00 PM and concluded at 01:45 PM.

This is for your information and records.

Thanking You,

FOR MEDICO INTERCONTINENTAL LIMITED



Samir D Shah
Managing Director
(DIN: 03350268)



V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783

C&AG REG NO. :- WR4659

MSME :- GJ01D0134595

GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED

We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN:0128769W)



Vipul Goswami
(Partner)

Mem No:119809

Place: -Ahmedabad

Date: - 14/08/2025

UDIN: 25119809BMLINZ1855



MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2025

(Rs in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		STANDALONE			STANDALONE
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Previous year ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited	Unaudited	Audited
Revenues					
1	Revenue from Operations	1346.68	1524.44	1151.99	6712.98
2	Other Income	24.19	13.28	10.32	50.77
3	Total Revenue (A)	1370.86	1537.73	1162.32	6763.75
Expenses					
(a)	Cost of materials consumed	0.000	0.00	0.000	0.00
(b)	Purchases of stock-in-trade	947.94	1397.30	949.63	5444.92
(c)	Changes in inventories of finished goods and stock-in-trade	128.51	-81.11	48.02	162.74
(d)	Employee benefits expense	50.88	53.69	37.51	174.06
(e)	Finance costs	43.52	23.10	9.49	67.22
(f)	Depreciation and amortisation expense	17.56	20.73	2.81	55.57
(g)	Other expenses	108.76	54.62	46.46	501.68
	Total Expenses (B)	1297.18	1468.33	1093.92	6406.20
5	Profit/(Loss) before exceptional items & tax (1-4)	73.68	69.40	68.40	357.55
6	Exceptional items	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	73.68	69.40	68.40	357.55
8	Tax expense	18.08	16.09	18.68	100.97
(a)	Current Tax	19.71	16.48	19.03	94.44
(b)	Deferred Tax	-1.63	-0.39	-0.35	6.54
9	Profit/(Loss) for the period from continuing operations (7-8)	55.60	53.31	49.71	256.58
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00
13	Profit/ (loss) for the period (After tax)	55.60	53.31	49.71	256.58
14	Other Comprehensive Income		0.00		0.00
15	Total Comprehensive Income for the period (13+14)	55.60	53.31	49.71	256.58
	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.00	1000.00	1000.00	1000.00
16	Earnings Per Equity Share of Rs. 10 each (for continuing Opertions)				
(a)	(Basic) - INR	0.56	0.53	0.50	2.57
(b)	(Diluted) - INR	0.56	0.53	0.50	2.57
17	Earnings Per Equity Share of Rs. 10 each (for discontinuing				
(a)	(Basic) - INR	0.00	0.00	0.00	0.000
(b)	(Diluted) - INR	0.00	0.00	0.00	0.000
18	Earnings Per Equity Share of Rs. 10 each (for continuing & discontinuing Operations)				
(a)	(Basic) - INR	0.56	0.53	0.50	2.57
(b)	(Diluted) - INR	0.56	0.53	0.50	2.57

- The above unaudited standalone financial results of the Company for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 14, 2025. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- During the quarter ended 30th June, 2025, the company is operating in single segment .so segment reporting is not applicable for this quarter, but segment information shall be provides when it applicable.
- Figures for the quarter ended 31 March 2025 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures up to the third quarter of the financial year.
- The previous period figures have been re-grouped / reclassified, wherever considered necessary, to make them comparable.

For, Medico Intercontinental Limited

SAMIR SHAH
MANAGING DIRECTOR
DIN:03350268



Place:Ahmedabad
Date:-14/08/2025



V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
MSME :- GJ01D0134595
GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED

We have reviewed the accompanying Statements of Consolidated Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the Holding Company") and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Parent Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



The Statement included the results of following subsidiary and joint venture Company: -

- 1.EVAGRACE PHARMA PRIVATE LIMITED
- 2.RITZ FORMULATIONS PRIVATE LIMITED
- 3.SUNGRACE PHARMA PRIVATE LIMITED
- 4.AZILLIAN HEALTHCARE PRIVATE LIMITED
- 5.CALBORN LIFESCIENCE PRIVATE LIMITED
- 6.MEDICO LAB (Joint venture)

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

During the quarter ended June 30, 2025, the Group has changed its accounting policy for investments in joint ventures (MEDICO LAB). Previously, the Group accounted for joint ventures using the proportionate consolidation method. Effective Q1 2025-26, the Group has adopted the equity method of accounting for investments in joint ventures, in accordance with Ind AS 28 "Investments in Associates and Joint Ventures."

The change in accounting policy has been applied retrospectively and the corresponding comparative figures for the previous periods have been restated to ensure comparability, as required under Ind AS 8 "Accounting Policies, Changes in Accounting Estimates and Errors."

A detailed reconciliation of the financial results previously reported under the proportionate consolidation method and the restated amounts under the equity method is provided in Note 5 to the consolidated results.

Our opinion is not modified in respect of these matters.



We did not review the interim financial results of the subsidiaries included in the consolidated unaudited financial results, whose financial results reflect, total revenues of Rs. 1064.73 Lakhs, total net profit after tax of Rs. (304.40) Lakhs for the quarter ended June 30, 2025 as considered in the Statement whose financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and joint venture is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN:0128769W)



Vipul Goswami
(Partner)

Mem No:119809

Date: -Ahmedabad

Place: -14/08/2025

UDIN: 25119809BMLIOA1443

MEDICO INTERCONTINENTAL LIMITED

CIN: L24100GJ1984PLC111413

Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com

Statement of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2025

(Rs in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		CONSOLIDATED			CONSOLIDATED
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Previous year ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited & Restated	Unaudited & Restated	Audited & Restated
	Revenues				
1	Revenue from Operations	2135.49	2115.64	1928.12	9531.53
2	Other Income	26.30	11.05	11.19	41.71
3	Total Revenue (A)	2161.79	2126.69	1939.32	9573.23
4	Expenses				
(a)	Cost of materials consumed	161.09	0.00	0.00	0.00
(b)	Purchases of stock-in-trade	1288.59	1808.02	1377.22	7252.23
(c)	Changes in inventories of finished goods and stock-in-trade	158.57	-126.19	152.9	192.24
(d)	Employee benefits expense	195.73	138.59	91.88	465.99
(e)	Finance costs	235.72	29.93	17.57	99.31
(f)	Depreciation and amortisation expense	61.87	27.65	8.18	78.69
(g)	Other expenses	264.37	101.27	142.65	802.66
	Total Expenses (B)	2365.93	1979.26	1790.37	8891.12
5	Profit/(Loss) before exceptional items & tax (1-4)	-204.14	147.43	148.95	682.11
6	Exceptional items	0.00	0.00	0.00	0.00
	Other Income	0.00		0.00	
7	Profit/(Loss) for the period from operations before tax (5+6)	-204.14	147.43	148.95	682.11
8	Tax expense				
(a)	Current Tax	47.49	32.89	40.66	186.59
(b)	Deferred Tax	41.84	33.13	39.52	175.44
		5.65	-0.24	1.14	11.15
9	Profit/(Loss) for the period from operations after tax (7-8)	-251.63	114.54	108.29	495.53
10	Share of Profit/ (Loss) of Associates and Joint Ventures	2.83	2.23	0.03	10.20
11	Profit After Tax and Share of Profit/ (Loss) of Associates and Joint Ventures for the period from continuing operations (9+10)	-248.80	116.77	108.32	505.73
12	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
14	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00
15	Profit/ (loss) for the period (After tax)	-248.80	116.77	108.32	505.73
16	Other Comprehensive Income				
(A)	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(B)	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	Other comprehensive Income/(Loss)	0.00	0.00	0.00	0.00
17	Total Comprehensive Income for the period (13+14)	-248.80	116.77	108.32	505.73
	Net profit attributable to:				
	Owners of the holding company	-67.82	116.77	108.32	505.73
	Non-controlling interest	-180.97	0.00	0.00	0.00
	Other comprehensive income attributable to:				
	Owners of the holding company	0.00	0.00	0.00	0.00
	Non-controlling interest	0.00	0.00	0.00	0.00
	Total comprehensive income attributable to:				
	Owners of the holding company	-67.82	116.77	108.32	505.73
	Non-controlling interest	-180.97	0.00	0.00	0.00
18	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.00	1000.00	1000.00	1000.00
19	Earnings Per Equity Share of Rs. 10 each (for continuing Opertions)				
(a)	(Basic) - INR	-0.68	1.17	1.08	5.06
(b)	(Diluted) - INR	-0.68	1.17	1.08	5.06
20	Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)				
(a)	(Basic) - INR	0.00	0.00	0.00	0.00
(b)	(Diluted) - INR	0.00	0.00	0.00	0.00
21	Earnings Per Equity Share of Rs. 10 each (for continuing & discontinuing Operations)				
(a)	(Basic) - INR	-0.68	1.17	1.08	5.06
(b)	(Diluted) - INR	-0.68	1.17	1.08	5.06

Arun



NOTES - CONSOLIDATED

- 1 The above unaudited consolidated financial results of the Company for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 14, 2025. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- 2 During the quarter ended June 30, 2025, the company is operating in single segment. So, segment reporting is not applicable for this quarter, but segment information shall be provided when it applicable.
- 3 Figures for the quarter ended 31st March 2025 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures up to the third quarter of the financial year.
- 4 The key standalone financial information of the Company is given below:

Particulars	Quarter ended			Year ended
	30/06/2025	31/03/2025	30/06/2024	31/03/2025
	Unaudited	Audited	Unaudited	Audited
Revenue from operations	1370.86	1537.73	1162.32	6763.75
Profit before tax	73.68	69.40	68.40	357.55
Net profit after tax	55.60	53.31	49.71	256.58
Total comprehensive income	55.60	53.31	49.71	256.58

5. During the quarter ended June 30, 2025, the Group has changed its accounting policy for investments in joint venture (MEDICO LAB). Previously, the Group accounted for joint venture using the proportionate consolidation method. Effective Q1 2025-26, the Group has adopted the equity method of accounting for investments in joint ventures, in accordance with Ind AS 28 "Investments in Associates and Joint Ventures."

The change in accounting policy has been applied retrospectively and the corresponding comparative figures for the previous periods have been restated to ensure comparability, as



required under Ind AS 8 "Accounting Policies, Changes in Accounting Estimates and Errors."

This change is effective from April 01, 2025, and as a result, the Group has ceased proportionate consolidation of MEDICO LAB and now recognizes its investment as a single line item in the consolidated balance sheet and its share of profit or loss in the consolidated income statement


Restated Comparative Figures as below

(Rs. In Lakhs)									
Particulars	Q4 FY 2024-25			Q1 FY 2024-25			FY 2024-25		
	As Previousl y Reported	Effect of Restat ement	As Restated	As Previou sly Reporte d	Effect of Restat ement	As Restated	As Previous ly Reporte d	Effect of Restate ment	As Restate d
Revenue	2,147.02	-20.33	2,126.69	1,835.98	103.34	1,939.32	9,637.12	-63.89	9,573.23
Expenses	1,994.70	-15.44	1,979.26	1,686.97	103.4	1,790.37	8,939.80	-48.68	8,891.12
Profit after Tax	116.77	-2.23	114.54	108.32	-0.03	108.29	505.73	-10.2	495.53
Share of Profit/(loss) from Joint Venture			2.23			0.03			10.2

To reflect this change and maintain comparability, prior period figures have been restated. The table below summarizes the quantitative impact on the Group's consolidated financial statements for the year ended 31st March 2025:

6. The previous period figures have been re-grouped / reclassified, wherever considered necessary, to make them comparable.

For, Medico Intercontinental Limited



SAMIR SHAH
MANAGING DIRECTOR
DIN: 03350268



Place: Ahmedabad
Date: -14/08/2025